Human parainfluenza virus type 3 expressing the respiratory syncytial virus pre-fusion F protein modified for virion packaging yields protective intranasal vaccine candidates.

Human respiratory syncytial virus (RSV) and parainfluenza virus type 3 (HPIV3) are among the most common viral causes of childhood bronchiolitis and pneumonia worldwide, and lack effective antiviral drugs or vaccines. Recombinant (r) HPIV3 was modified to express the RSV fusion (F) glycoprotein, the...

Full description

Bibliographic Details
Main Authors: Xueqiao Liu, Bo Liang, Xiang Liu, Emerito Amaro-Carambot, Sonja Surman, Peter D Kwong, Barney S Graham, Peter L Collins, Shirin Munir
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2020-01-01
Series:PLoS ONE
Online Access:https://doi.org/10.1371/journal.pone.0228572
id doaj-5f5445bd5a834a39a953e5141230cfd8
record_format Article
spelling doaj-5f5445bd5a834a39a953e5141230cfd82021-03-03T21:29:03ZengPublic Library of Science (PLoS)PLoS ONE1932-62032020-01-01152e022857210.1371/journal.pone.0228572Human parainfluenza virus type 3 expressing the respiratory syncytial virus pre-fusion F protein modified for virion packaging yields protective intranasal vaccine candidates.Xueqiao LiuBo LiangXiang LiuEmerito Amaro-CarambotSonja SurmanPeter D KwongBarney S GrahamPeter L CollinsShirin MunirHuman respiratory syncytial virus (RSV) and parainfluenza virus type 3 (HPIV3) are among the most common viral causes of childhood bronchiolitis and pneumonia worldwide, and lack effective antiviral drugs or vaccines. Recombinant (r) HPIV3 was modified to express the RSV fusion (F) glycoprotein, the major RSV neutralization and protective antigen, providing a live intranasal bivalent HPIV3/RSV vaccine candidate. This extends previous studies using a chimeric bovine-human PIV3 vector (rB/HPIV3). One advantage is that rHPIV3 expresses all of the HPIV3 antigens compared to only two for rB/HPIV3. In addition, the use of rHPIV3 as vector should avoid excessive attenuation following addition of the modified RSV F gene, which may occur with rB/HPIV3. To enhance its immunogenicity, RSV F was modified (i) to increase the stability of the prefusion (pre-F) conformation and (ii) by replacement of its transmembrane (TM) and cytoplasmic tail (CT) domains with those of HPIV3 F (H3TMCT) to increase incorporation in the vector virion. RSV F (+/- H3TMCT) was expressed from the first (F/preN) or the second (F/N-P) gene position of rHPIV3. The H3TMCT modification dramatically increased packaging of RSV F into the vector virion and, in hamsters, resulted in significant increases in the titer of high-quality serum RSV-neutralizing antibodies, in addition to the increase conferred by pre-F stabilization. Only F-H3TMCT/preN replication was significantly attenuated in the nasal turbinates by the RSV F insert. F-H3TMCT/preN, F/N-P, and F-H3TMCT/N-P provided complete protection against wt RSV challenge. F-H3TMCT/N-P exhibited the most stable and highest expression of RSV F, providing impetus for its further development.https://doi.org/10.1371/journal.pone.0228572
collection DOAJ
language English
format Article
sources DOAJ
author Xueqiao Liu
Bo Liang
Xiang Liu
Emerito Amaro-Carambot
Sonja Surman
Peter D Kwong
Barney S Graham
Peter L Collins
Shirin Munir
spellingShingle Xueqiao Liu
Bo Liang
Xiang Liu
Emerito Amaro-Carambot
Sonja Surman
Peter D Kwong
Barney S Graham
Peter L Collins
Shirin Munir
Human parainfluenza virus type 3 expressing the respiratory syncytial virus pre-fusion F protein modified for virion packaging yields protective intranasal vaccine candidates.
PLoS ONE
author_facet Xueqiao Liu
Bo Liang
Xiang Liu
Emerito Amaro-Carambot
Sonja Surman
Peter D Kwong
Barney S Graham
Peter L Collins
Shirin Munir
author_sort Xueqiao Liu
title Human parainfluenza virus type 3 expressing the respiratory syncytial virus pre-fusion F protein modified for virion packaging yields protective intranasal vaccine candidates.
title_short Human parainfluenza virus type 3 expressing the respiratory syncytial virus pre-fusion F protein modified for virion packaging yields protective intranasal vaccine candidates.
title_full Human parainfluenza virus type 3 expressing the respiratory syncytial virus pre-fusion F protein modified for virion packaging yields protective intranasal vaccine candidates.
title_fullStr Human parainfluenza virus type 3 expressing the respiratory syncytial virus pre-fusion F protein modified for virion packaging yields protective intranasal vaccine candidates.
title_full_unstemmed Human parainfluenza virus type 3 expressing the respiratory syncytial virus pre-fusion F protein modified for virion packaging yields protective intranasal vaccine candidates.
title_sort human parainfluenza virus type 3 expressing the respiratory syncytial virus pre-fusion f protein modified for virion packaging yields protective intranasal vaccine candidates.
publisher Public Library of Science (PLoS)
series PLoS ONE
issn 1932-6203
publishDate 2020-01-01
description Human respiratory syncytial virus (RSV) and parainfluenza virus type 3 (HPIV3) are among the most common viral causes of childhood bronchiolitis and pneumonia worldwide, and lack effective antiviral drugs or vaccines. Recombinant (r) HPIV3 was modified to express the RSV fusion (F) glycoprotein, the major RSV neutralization and protective antigen, providing a live intranasal bivalent HPIV3/RSV vaccine candidate. This extends previous studies using a chimeric bovine-human PIV3 vector (rB/HPIV3). One advantage is that rHPIV3 expresses all of the HPIV3 antigens compared to only two for rB/HPIV3. In addition, the use of rHPIV3 as vector should avoid excessive attenuation following addition of the modified RSV F gene, which may occur with rB/HPIV3. To enhance its immunogenicity, RSV F was modified (i) to increase the stability of the prefusion (pre-F) conformation and (ii) by replacement of its transmembrane (TM) and cytoplasmic tail (CT) domains with those of HPIV3 F (H3TMCT) to increase incorporation in the vector virion. RSV F (+/- H3TMCT) was expressed from the first (F/preN) or the second (F/N-P) gene position of rHPIV3. The H3TMCT modification dramatically increased packaging of RSV F into the vector virion and, in hamsters, resulted in significant increases in the titer of high-quality serum RSV-neutralizing antibodies, in addition to the increase conferred by pre-F stabilization. Only F-H3TMCT/preN replication was significantly attenuated in the nasal turbinates by the RSV F insert. F-H3TMCT/preN, F/N-P, and F-H3TMCT/N-P provided complete protection against wt RSV challenge. F-H3TMCT/N-P exhibited the most stable and highest expression of RSV F, providing impetus for its further development.
url https://doi.org/10.1371/journal.pone.0228572
work_keys_str_mv AT xueqiaoliu humanparainfluenzavirustype3expressingtherespiratorysyncytialvirusprefusionfproteinmodifiedforvirionpackagingyieldsprotectiveintranasalvaccinecandidates
AT boliang humanparainfluenzavirustype3expressingtherespiratorysyncytialvirusprefusionfproteinmodifiedforvirionpackagingyieldsprotectiveintranasalvaccinecandidates
AT xiangliu humanparainfluenzavirustype3expressingtherespiratorysyncytialvirusprefusionfproteinmodifiedforvirionpackagingyieldsprotectiveintranasalvaccinecandidates
AT emeritoamarocarambot humanparainfluenzavirustype3expressingtherespiratorysyncytialvirusprefusionfproteinmodifiedforvirionpackagingyieldsprotectiveintranasalvaccinecandidates
AT sonjasurman humanparainfluenzavirustype3expressingtherespiratorysyncytialvirusprefusionfproteinmodifiedforvirionpackagingyieldsprotectiveintranasalvaccinecandidates
AT peterdkwong humanparainfluenzavirustype3expressingtherespiratorysyncytialvirusprefusionfproteinmodifiedforvirionpackagingyieldsprotectiveintranasalvaccinecandidates
AT barneysgraham humanparainfluenzavirustype3expressingtherespiratorysyncytialvirusprefusionfproteinmodifiedforvirionpackagingyieldsprotectiveintranasalvaccinecandidates
AT peterlcollins humanparainfluenzavirustype3expressingtherespiratorysyncytialvirusprefusionfproteinmodifiedforvirionpackagingyieldsprotectiveintranasalvaccinecandidates
AT shirinmunir humanparainfluenzavirustype3expressingtherespiratorysyncytialvirusprefusionfproteinmodifiedforvirionpackagingyieldsprotectiveintranasalvaccinecandidates
_version_ 1714816614830964736